BLUEPRINT MEDICINES CORP (BPMC)

US09627Y1091 - Common Stock

90.63  -3.74 (-3.96%)

After market: 90.63 0 (0%)

Fundamental Rating

3

Overall BPMC gets a fundamental rating of 3 out of 10. We evaluated BPMC against 561 industry peers in the Biotechnology industry. BPMC may be in some trouble as it scores bad on both profitability and health. BPMC is valued quite expensively, but it does show have an excellent growth rating.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

BPMC had negative earnings in the past year.
In the past year BPMC has reported a negative cash flow from operations.
BPMC had negative earnings in 4 of the past 5 years.
BPMC had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of -10.67%, BPMC belongs to the best of the industry, outperforming 86.49% of the companies in the same industry.
BPMC's Return On Equity of -40.89% is fine compared to the rest of the industry. BPMC outperforms 72.25% of its industry peers.
Industry RankSector Rank
ROA -10.67%
ROE -40.89%
ROIC N/A
ROA(3y)-47.02%
ROA(5y)-34.38%
ROE(3y)-187.61%
ROE(5y)-123.27%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of BPMC (97.01%) is better than 96.94% of its industry peers.
In the last couple of years the Gross Margin of BPMC has remained more or less at the same level.
BPMC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.14%
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BPMC has been increased compared to 1 year ago.
BPMC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BPMC is higher compared to a year ago.

2.2 Solvency

BPMC has an Altman-Z score of 1.35. This is a bad value and indicates that BPMC is not financially healthy and even has some risk of bankruptcy.
BPMC has a Altman-Z score of 1.35. This is in the better half of the industry: BPMC outperforms 67.21% of its industry peers.
A Debt/Equity ratio of 1.09 is on the high side and indicates that BPMC has dependencies on debt financing.
The Debt to Equity ratio of BPMC (1.09) is worse than 78.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF N/A
Altman-Z 1.35
ROIC/WACCN/A
WACC10.99%

2.3 Liquidity

BPMC has a Current Ratio of 3.32. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.32, BPMC is doing worse than 60.00% of the companies in the same industry.
BPMC has a Quick Ratio of 3.27. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.27, BPMC perfoms like the industry average, outperforming 40.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.32
Quick Ratio 3.27

More info and screens

7

3. Growth

3.1 Past

BPMC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.44%, which is quite impressive.
BPMC shows a strong growth in Revenue. In the last year, the Revenue has grown by 100.84%.
The Revenue has been growing by 41.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)47.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.55%
Revenue 1Y (TTM)100.84%
Revenue growth 3Y-32.02%
Revenue growth 5Y41.16%
Sales Q2Q%126.61%

3.2 Future

The Earnings Per Share is expected to grow by 25.41% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 40.29% on average over the next years. This is a very strong growth
EPS Next Y88%
EPS Next 2Y37.3%
EPS Next 3Y29.93%
EPS Next 5Y25.41%
Revenue Next Year107.83%
Revenue Next 2Y70.17%
Revenue Next 3Y56.76%
Revenue Next 5Y40.29%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BPMC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BPMC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BPMC's earnings are expected to grow with 29.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.3%
EPS Next 3Y29.93%

More info and screens

0

5. Dividend

5.1 Amount

BPMC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (1/8/2025, 8:00:01 PM)

After market: 90.63 0 (0%)

90.63

-3.74 (-3.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)02-13 2025-02-13/amc
Inst Owners106.45%
Inst Owner Change0%
Ins Owners0.82%
Ins Owner Change-2.39%
Market Cap5.76B
Analysts80
Price Target128.09 (41.33%)
Short Float %7.2%
Short Ratio6.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.48%
Min EPS beat(2)9.73%
Max EPS beat(2)39.24%
EPS beat(4)4
Avg EPS beat(4)20.91%
Min EPS beat(4)9.73%
Max EPS beat(4)39.24%
EPS beat(8)8
Avg EPS beat(8)16.37%
EPS beat(12)10
Avg EPS beat(12)-7.56%
EPS beat(16)13
Avg EPS beat(16)-5.51%
Revenue beat(2)1
Avg Revenue beat(2)14.85%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)30.77%
Revenue beat(4)3
Avg Revenue beat(4)13.32%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)30.77%
Revenue beat(8)7
Avg Revenue beat(8)18.23%
Revenue beat(12)10
Avg Revenue beat(12)21%
Revenue beat(16)13
Avg Revenue beat(16)17.8%
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)36.17%
EPS NY rev (1m)-0.53%
EPS NY rev (3m)23.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)21.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.25
P/FCF N/A
P/OCF N/A
P/B 18.39
P/tB 18.39
EV/EBITDA N/A
EPS(TTM)-4.83
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-3.94
FCFYN/A
OCF(TTM)-3.81
OCFYN/A
SpS6.84
BVpS4.93
TBVpS4.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.67%
ROE -40.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.01%
FCFM N/A
ROA(3y)-47.02%
ROA(5y)-34.38%
ROE(3y)-187.61%
ROE(5y)-123.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.14%
GM growth 5YN/A
F-Score3
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.34%
Cap/Sales 1.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.32
Quick Ratio 3.27
Altman-Z 1.35
F-Score3
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)87.15%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.17%
Cap/Sales(5y)6.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.55%
EPS Next Y88%
EPS Next 2Y37.3%
EPS Next 3Y29.93%
EPS Next 5Y25.41%
Revenue 1Y (TTM)100.84%
Revenue growth 3Y-32.02%
Revenue growth 5Y41.16%
Sales Q2Q%126.61%
Revenue Next Year107.83%
Revenue Next 2Y70.17%
Revenue Next 3Y56.76%
Revenue Next 5Y40.29%
EBIT growth 1Y48.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.02%
EBIT Next 3Y31.48%
EBIT Next 5Y21.79%
FCF growth 1Y37.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.71%
OCF growth 3YN/A
OCF growth 5YN/A